Blueshift Asset Management LLC purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 16,482 shares of the company’s stock, valued at approximately $435,000. Several other large investors have also recently made changes to […]
BMO Capital Markets assumed coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a research note published on Wednesday morning, MarketBeat reports. The firm issued a market perform rating and a $37.00 price objective on the stock. A number of other brokerages also recently issued reports on BBIO. Citigroup assumed coverage on BridgeBio […]
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1 […]
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) and Equillium (NASDAQ:EQ – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations. Institutional & Insider Ownership 90.9% of BridgeBio Pharma shares […]